World Mental Health Day 2020
October 10 is World Mental Health Day, 2020. We highlight the progress made in mental health therapeutics through the COVID-19 pandemic.
News
neuroCare Group targeting ASX or NASDAQ First North IPO in 18 months
Interview with neuroCare Founder & Executive Chairman Thomas Mechtersheimer
neuroCare Group receives 2nd investment from bm|t to fund further expansion
The investment will not only finance the company´s further expansion, including its Japan market entry, but also will safeguard neuroCare’s growth and planned IPO beyond the current COVID-19 crisis.
More News
Personalised Digital Therapeutics for Mental Health & Performance
neuroCare is innovating mental health and performance by personalising therapy following a detailed assessment. neuroCare’s objective, measurable and effective approach is based on our natural ability to learn (neuroplasticity) and technology to speed up the learning (neuromodulation).
neuroCare helps individuals to improve their self-regulation and hence is a sustainable solution. The neuroCare Group provides Digital Therapeutics and Teletherapy and our vertical integration and know-how in Science, Neuromodulation Technology and clinical SOP’s is unique.
Our global network of clinics
Comprehensive assessments to understand each individual client
Psychiatry has traditionally been one of the only medical fields which has not been able to take a close look at the organ it is treating. With recent advances in technologies and diagnostic measures, practitioners in mental health now have access to innovative tools to make more informed assessments of the individual client they see.
At neuroCare, our therapists are trained to use these tools and have been supervised by leading neuroscientists and practitioners to make an informed and holistic assessment of a client’s presenting symptoms.
Supervision, Training and evaluation of neuromodulation
Our training courses are designed to instruct clinicians, academics and researchers in the use of neuromodulation technology, with a goal to apply these techniques in clinical practices or research settings. Under the guidance of our expert trainers, students receive substantial hands-on experience with rTMS, tDCS and neurofeedback technology and its application. Over the last 10 years we have trained more than 1,000 professionals from over 30 countries in the use of neuromodulation techniques. We have continually received outstanding feedback from our trainees, with an average evaluation of 8.9/10.
Learn more about our training courses
Leading developer and manufacturer of EEG and tES technologies
For more than ten years the neuroConn brand has been associated with practice-oriented medical technology used in neuroscience and clinical research, as well as in the diagnosis and treatment of neuropsychological disorders. In close cooperation with leading research institutions and clinics worldwide, neuroConn technology is designed following the latest medical research standards. In this way we provide users with standardised and clinically evaluated protocols in transcranial Electrical Stimulation (tDCS, tACS, tRNS) as well as Neurofeedback of Slow Cortical Potentials.
Learn more about our product range
